Description:
EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P by EDWARDS LIFESCIENCES LLC.
The EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P is an exceptional product by EDWARDS LIFESCIENCES LLC., dedicated to improving patient's lives. It is a tissue heart valve that is primarily used in open heart surgery for valve replacement.
The unique stentless design of the Model 2600P paves the way for a smoother and more natural blood flow, leading to improved hemodynamics. The use of this bioprosthesis can minimize the pressure gradient and potentially increase valve durability.
Using the latest research and technology, the Model 2600P is manufactured from bovine pericardial tissue treated with Edwards' proprietary ThermaFix process. This process enhances the tissue's performance and durability, reducing the potential for calcification and tissue deterioration.
Healthcare providers may benefit from fewer reoperations due to its superior durability compared to traditional heart valve implants. And for the patient, it can offer an enhanced quality of life, fewer medical complications, and an overall longer life expectancy.
Trust the EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P for optimal heart valve performance.
Primary Use:
Primary Usage of the 'Edwards Prima Plus Stentless Bioprosthesis Model 2600P'
The
Edwards Prima Plus Stentless Bioprosthesis Model 2600P is a pivotal medical device used in the genre of 'Heart Valve Implants'. Manufactured by Edwards Lifesciences Corporation, this specialty device is primarily used to replace a patient's diseased, damaged, or malfunctioning aortic valve.
Functionality and Procedure
Aortic heart valve replacement is a significant, life-saving surgery where a patient's aortic valve is replaced with a prosthetic valve - in this case, the
Edwards Prima Plus Stentless Bioprosthesis Model 2600P. This device essentially emulates the action of a healthy valve, regulating the blood flow from the heart into the aorta, the main artery
How It Works:
Understanding the EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P (Heart Valve Implants)
The
EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P is an advanced medical device used in the realm of cardiac health, notably for patients requiring a
heart valve replacement. It delivers an effective solution for mitigating the problems connected with problematic or diseased heart valves.
Functioning of the EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS
This
bio-prosthesis operates by mimicking a healthy, naturally functioning heart valve. A notable characteristic of this type of prosthesis is the exclusion of a stent. A
stent is typically a rigid frame utilized to prop open a valve or blood vessel. A 'stentless' prosthesis, as in the case of EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P, does not incorporate such a frame.
The principal benefit of this stentless design is that it permits a more natural flow of blood through the valve, which can lead to increased longevity for the prosthesis as well as other potential health benefits for the patient. This natural blood flow closely emulates the way a robust, healthy heart valve facilitates blood flow in a heart that is not affected by any condition or ailment.
Accurate and Safe Functioning
The EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P is meticulously designed with safety and durability in mind. It is typically implanted in a patient's body by a surgical procedure involving the removal of the damaged heart valve.
The device is constructed from porcine, or pig, heart valves, which are carefully treated to ensure long-term durability and compatibility with the human body. The porcine heart valves are thoroughly sterilized and detoxified in a carefully controlled procedure, a treatment process known as
decellularization.
In conclusion, the EDWARDS PRIMA PLUS STENTLESS BIOPROSTHESIS MODEL 2600P is a highly sophisticated medical device that provides a reliable solution for victims of heart valve diseases, potentially improving their quality of life and heightening their prospects for improved health outcomes.